Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
J Patient Saf. 2021 Dec 1;17(8):e1179-e1185. doi: 10.1097/PTS.0000000000000914.
This study investigated severe medication errors (MEs) reported to the National Supervisory Authority for Welfare and Health (Valvira) in Finland and evaluated how the incident documentation applies to learning from errors.
This study was a retrospective document analysis consisting of medication-related complaints and authoritative statements investigated by Valvira in 2013 to 2017 (n = 58).
Medication errors caused death or severe harm in 52% (n = 30) of the cases (n = 58). The majority (83%; n = 48) of the incidents concerned patients older than 60 years. Most likely, the errors occurred in prescribing (n = 38; 47%), followed by administration (n = 15; 19%) and monitoring (n = 14; 17%). The error process often included many failures (n = 24; 41%) or more than one health professional (n = 16; 28%). Antithrombotic agents (n = 17; 13%), opioids (n = 10; 8%), and antipsychotics (n = 10; 8%) were the therapeutic groups most commonly involved in the errors. Almost all error cases (91%; n = 53) were assessed as likely or potentially preventable. In 60% (n = 35) of the cases, the organization reported actions taken to improve medication safety after the occurrence of the investigated incident.
Medication errors reported to the national health care supervisory authority provide a valuable source of risk information and should be used for learning from severe errors at the level of health care systems. High age remains a key risk factor to severe MEs, which may be associated with a wide range of medications including those not typically perceived as high-alert medications or high-risk administration routes. Despite being complex processes, the severe MEs have a great potential to lead to developing systems, processes, resources, and competencies of health care organizations.
本研究调查了向芬兰国家福利与健康监督局(Valvira)报告的严重用药错误(ME),并评估了事件记录如何应用于错误学习。
本研究是一项回顾性文件分析,包括 Valvira 于 2013 年至 2017 年调查的与药物相关的投诉和权威声明(n=58)。
用药错误导致 52%(n=30)的病例死亡或严重伤害(n=58)。大多数事件(83%;n=48)涉及 60 岁以上的患者。最有可能的是,错误发生在处方(n=38;47%),其次是给药(n=15;19%)和监测(n=14;17%)。错误过程通常包括许多失败(n=24;41%)或多个卫生专业人员(n=16;28%)。抗血栓形成剂(n=17;13%)、阿片类药物(n=10;8%)和抗精神病药(n=10;8%)是最常涉及错误的治疗组。几乎所有错误案例(91%;n=53)均被评估为可能或潜在可预防。在 60%(n=35)的案例中,报告了在发生调查事件后采取的旨在提高药物安全性的行动。
向国家医疗保健监督机构报告的用药错误为风险信息提供了宝贵的来源,应将其用于从医疗保健系统层面学习严重错误。高龄仍然是导致严重 MEs 的关键风险因素,这可能与包括那些通常不被视为高警示药物或高风险给药途径的广泛药物有关。尽管这些严重的 MEs 是复杂的过程,但它们有很大的潜力为医疗保健组织的系统、流程、资源和能力发展提供信息。